ArticleTranslational pediatrics2026
RPS29 as a potential early diagnostic biomarker for necrotizing enterocolitis: validation from transcriptomic and proteomic cohorts.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Necrotizing enterocolitis (NEC) is a life-threatening gastrointestinal disorder in neonates, and its early diagnosis remains challenging. RPS29, a ribosomal protein associated with cellular stress and inflammation, was identified as significantly differentially expressed in the discovery proteomic screening. This study aimed to identify RPS29 as a potential biomarker for the early diagnosis of NEC. Methods: In a prospective cohort, plasma samples were analyzed using Astral proteomics (controls, n=12; NEC stage I, n=12; NEC stage II, n=13; NEC stage III, n=12). Transcriptomic profiling was performed to assess mRNA expression in intestinal tissues from controls (n=5) and NEC patients (n=5). Plasma protein levels were further quantified by enzyme-linked immunosorbent assay (ELISA), while their expression in intestinal tissues from NEC infants and NEC mouse models was validated by immunofluorescence and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The diagnostic performance of plasma protein was evaluated using receiver operating characteristic (ROC) curves and compared with routine hematological parameters. Results: RPS29 showed significantly decreased levels in the plasma of infants with NEC in the proteomic dataset, particularly in Bell stage I NEC. Plasma ELISA of RPS29 protein also revealed a significant decrease in RPS29 levels in Bell stage I NEC. RPS29 protein showed favorable diagnostic performance, with areas under the curve (AUCs) of 0.9679 and 0.9306 at stages II and III, and as high as 0.9861 at stage I. Intestine transcriptomics revealed a significant decrease of RPS29 in NEC patients, which was consistent with downregulation of RPS29 protein and mRNA expression validated in both NEC patients and mouse models. Conclusions: Plasma RPS29 protein exhibits potential diagnostic accuracy for early-stage NEC and represents a promising biomarker for its early detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.